THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/294 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846095233355350016 |
|---|---|
| author | Xenofon Papanikolaou Bart Barlogie Saad Usmani |
| author_facet | Xenofon Papanikolaou Bart Barlogie Saad Usmani |
| author_sort | Xenofon Papanikolaou |
| collection | DOAJ |
| description | Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenalidomide. Little is known about the new antimyeloma agents in the context of therapy related myeloid malignanices. The duration of treatment and the time from diagnosis are the main contributing factors in alkylating induced myeloid malignancies which occur 5-10 years after treatment, chromosome 5 and 7 abnormalities being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing factor per se in multiple myeloma. In a number of large published series, all the factors related with therapy-induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce mainly acute leukemias which invariably correlate with dysregulation of the MLL gene. Radiotherapy causes therapy related myelodysplasia if applied in bone marrow producing areas, especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the risk for therapy related myeloid malignancies drops sharply by 10 years after the treatment. |
| format | Article |
| id | doaj-art-2c34976817804011a3af5a5eaac13cac |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2011-10-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-2c34976817804011a3af5a5eaac13cac2025-01-02T11:15:16ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-10-0131e2011047e201104710.4084/mjhid.2011.047186THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMAXenofon Papanikolaou0Bart BarlogieSaad Usmani, AND SAAD Z. USMANITherapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenalidomide. Little is known about the new antimyeloma agents in the context of therapy related myeloid malignanices. The duration of treatment and the time from diagnosis are the main contributing factors in alkylating induced myeloid malignancies which occur 5-10 years after treatment, chromosome 5 and 7 abnormalities being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing factor per se in multiple myeloma. In a number of large published series, all the factors related with therapy-induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce mainly acute leukemias which invariably correlate with dysregulation of the MLL gene. Radiotherapy causes therapy related myelodysplasia if applied in bone marrow producing areas, especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the risk for therapy related myeloid malignancies drops sharply by 10 years after the treatment.http://www.mjhid.org/index.php/mjhid/article/view/294Myeloma, Therapy related leukemia, Therapy related neoplasm |
| spellingShingle | Xenofon Papanikolaou Bart Barlogie Saad Usmani THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA Mediterranean Journal of Hematology and Infectious Diseases Myeloma, Therapy related leukemia, Therapy related neoplasm |
| title | THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA |
| title_full | THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA |
| title_fullStr | THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA |
| title_full_unstemmed | THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA |
| title_short | THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA |
| title_sort | therapy related myeloid malignancies in myeloma |
| topic | Myeloma, Therapy related leukemia, Therapy related neoplasm |
| url | http://www.mjhid.org/index.php/mjhid/article/view/294 |
| work_keys_str_mv | AT xenofonpapanikolaou therapyrelatedmyeloidmalignanciesinmyeloma AT bartbarlogie therapyrelatedmyeloidmalignanciesinmyeloma AT saadusmani therapyrelatedmyeloidmalignanciesinmyeloma |